Last reviewed · How we verify

Indiana Hand to Shoulder Center — Portfolio Competitive Intelligence Brief

Indiana Hand to Shoulder Center pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Clostridial collagenase injectable Clostridial collagenase injectable marketed
Injectable clostridial collagenase Injectable clostridial collagenase marketed Collagenase enzyme Collagen (types I and III) Orthopedics / Hand Surgery

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Charitable Union for the Research and Education of Peyronie's Disease · 1 shared drug class
  2. DMR Research, PLLC · 1 shared drug class
  3. Hospital for Special Surgery, New York · 1 shared drug class
  4. Luxurgery · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Indiana Hand to Shoulder Center:

Cite this brief

Drug Landscape (2026). Indiana Hand to Shoulder Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/indiana-hand-to-shoulder-center. Accessed 2026-05-17.

Related